Psychopharm Review (PR)

Psychopharm Review is a peer-reviewed journal dedicated to advancing knowledge in psychopharmacology and related therapeutic approaches. It provides timely reports on drug therapies, psychiatric treatments, and device-based interventions for mental health disorders. The journal serves as a platform for clinicians, researchers, and academicians to stay updated on developments in psychiatric pharmacology, including clinical trials, drug efficacy, safety profiles, and emerging therapeutic technologies. Its interdisciplinary scope bridges psychiatry, psychology, and pharmacology, making it a valuable resource for professionals seeking evidence-based insights into treatment strategies. Published by Lippincott Williams & Wilkins, now part of Wolters Kluwer Health, the journal is accessible in both print and online formats. Indexed in major databases such as SCOPUS and Thomson Reuters Master Journal List, Psychopharm Review ensures wide visibility and credibility in the academic community. While specific editorial leadership details are not publicly available, the journal maintains rigorous standards of peer review and scholarly integrity. Its mission is to enhance clinical practice and research in psychopharmacology, contributing to improved patient outcomes in mental health care.

Psychopharm Review (PR) is :-

• International, Peer-Reviewed, Open Access, Refereed, Emergency Medicine, General Medicine, General Psychology, Neuroscience (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), linical trials, drug efficacy, safety profiles, emerging therapeutic technologies, bridges psychiatry, psychology, and pharmacology , Online or Print , Irregular Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1936-9255, E-ISSN: 2163-8292, Established: 2007,
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE